Precision Oncology News

Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

Lantern Pharma Making Headway in Using AI to Revive Old Drugs, Develop New Compounds

Premium

Lantern Pharma is using its RADR platform to repurpose two drugs currently in clinical trials and advance a new drug in preclinical testing.

Eli Lilly, Sermonix Pharma Partner on Phase II Trial of Drug Combo in Metastatic Breast Cancer

The open-label, multi-center trial will start enrolling patients in the third quarter to evaluate the safety of lasofoxifene combined with abemaciclib.

Turning Point Therapeutics, Zai Lab Enter License Agreement for Repotrectinib in Greater China

Repotrectinib is an investigational drug intended for the treatment of patients with advanced solid tumors harboring ROS1, NTRK1-3, or ALK molecular rearrangements.

EMA Accepts Daiichi Sankyo's Application for Enhertu in HER2-Positive Breast Cancer

Enhertu, or trastuzumab deruxtecan, will also receive accelerated assessment by the European Medicines Agency's Committee for Medicinal Products for Human Use.

Immunomedics' Trodelvy Improves Survival in Patients With Pretreated Triple-Negative Breast Cancer

In the Phase III ASCENT trial, antibody-drug conjugate Trodelvy was able to improve clinical outcomes in patients with relapsed or refractory metastatic TNBC who received at least two therapies prior.

Jul 01, 2020

Bolt Biotherapeutics Raises $93.5M in Series C Financing to Advance BDC-1001

Jul 01, 2020

Daiichi Sankyo Adds TNBC Cohort to TROP2-Directed Antibody Study

Jun 29, 2020

Aileron Therapeutics Enrolling TP53-Mutated Lung Cancer Patients in Phase IB/II Study

Jun 26, 2020

Artiva Biotherapeutics Launches With $78 Million Series A Raise, Aims to Advance CAR-NK Drugs

Jun 24, 2020

Roche's Tiragolumab, Tecentriq Efficacy in PD-L1 Positive NSCLC Further Demonstrated at AACR

Jun 23, 2020

Oncolytics Biotech Doses First Breast Cancer Patient in Phase II Study of Virus-Based Therapy Combo

Jun 22, 2020

Onconova to Enroll Patients With KRAS-Mutated Lung Cancer in Phase I/II Rigosertib Trials

Jun 22, 2020

BioNTech's Personalized Cancer Vaccine, Tecentriq Yield Few Responses but Promising Immune Activity

Jun 19, 2020

Aprea's Drug for TP53-Mutant Cancers Moves Into Registrational Trials for Myelodysplastic Syndromes

Premium

Jun 18, 2020

FDA Approves Epizyme's Tazverik, Roche CDx for EZH2-Mutated Follicular Lymphoma Patients

Jun 18, 2020

Israeli Startup Curesponse Targets European Pharma Market With Drug Prediction, Development Service

Premium

Jun 16, 2020

Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year

Premium

Jun 15, 2020

Bellicum's IND for CAR T Cell Therapy in HER2-Positive Solid Tumors Accepted by FDA

Jun 12, 2020

Agios Sells Royalty Rights to AML Drug Idhifa for $255 Million

Jun 10, 2020

UbiVac, BMS Collaborate on Immunotherapy Clinical Trial for Triple-Negative Breast Cancer

Jun 10, 2020

Bayer Continuing Vitrakvi Studies to Improve Understanding of Activity In Specific Tumor Types

Premium

Jun 09, 2020

Revolution Medicines Doses First Patient in Study of SHP2 Inhibitor With Amgen's KRAS Inhibitor

Jun 03, 2020

NKMax America's NK Cell Therapy Combination Accepted by FDA for HER2, EGFR-Expressing Cancers

Jun 02, 2020

Blueprint's Positive Pralsetinib Data Places New Option on Horizon for RET-Altered Cancer Patients

Premium

May 30, 2020

ASCO Presentations Highlight Advances in Antibody Treatments for Molecularly Defined Lung Cancers